5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 7.75▼ | 7.72▲ | 7.72▲ | 8.61▼ | 7.73▲ |
MA10 | 7.72▲ | 7.71▲ | 7.88▼ | 8.10▼ | 8.18▼ |
MA20 | 7.72▲ | 7.96▼ | 8.41▼ | 7.79▼ | 8.87▼ |
MA50 | 7.71▲ | 8.56▼ | 8.45▼ | 9.03▼ | 12.74▼ |
MA100 | 7.87▼ | 8.37▼ | 7.84▼ | 9.03▼ | 11.47▼ |
MA200 | 8.37▼ | 7.84▼ | 8.06▼ | 10.69▼ | 10.35▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.011▲ | -0.102▼ | 0.164▲ | 0.062▲ |
RSI | 52.546▲ | 31.331▼ | 34.026▼ | 44.928▼ | 42.565▼ |
STOCH | 77.565 | 38.843 | 15.941▼ | 71.740 | 15.005▼ |
WILL %R | -51.549 | -75.607▼ | -85.915▼ | -66.926 | -88.003▼ |
CCI | 98.789 | -27.868 | -67.951 | 0.279 | -68.096 |
Monday, January 13, 2025 04:00 AM
Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA ...
|
Wednesday, January 08, 2025 04:01 PM
NASDAQ:EYPT opened at $9.11 on Tuesday. EyePoint Pharmaceuticals has a 1 year low of $6.90 and a 1 year high of $30.99. The stock has a market cap of $621.77 million, a P/E ratio of -4.56 and a ...
|
Wednesday, January 08, 2025 08:26 AM
Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), retaining the price ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/01/25 | 8.15 | 8.36 | 7.5401 | 7.75 | 886,870 |
10/01/25 | 9.00 | 9.01 | 8.16 | 8.34 | 751,897 |
08/01/25 | 9.20 | 9.35 | 8.83 | 9.11 | 804,256 |
07/01/25 | 9.30 | 9.47 | 8.785 | 9.19 | 692,192 |
06/01/25 | 8.50 | 9.20 | 8.37 | 8.68 | 949,209 |
03/01/25 | 8.05 | 8.42 | 8.01 | 8.26 | 824,760 |
02/01/25 | 7.59 | 8.42 | 7.5445 | 8.03 | 1,132,171 |
31/12/24 | 7.09 | 7.485 | 6.985 | 7.45 | 569,276 |
30/12/24 | 7.14 | 7.20 | 6.91 | 7.02 | 843,905 |
27/12/24 | 7.57 | 7.74 | 7.19 | 7.20 | 673,675 |
|
|
||||
|
|
||||
|
|